TNGX · Tango Therapeutics, Inc. · Executive Compensation
$22.43
-0.65 (-2.82%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$4.20B
Shares
168.61M
Volume · Oct 6
585.31K
Avg daily vol (3M)
2.59M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | Executive Chairman | $2,823,992 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $1,721,080 |
| Daniella Beckman | Former Chief Financial Officer | $1,155,775 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $6,541,200 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $3,777,318 |
| Daniella Beckman | Chief Financial Officer | $3,166,290 |
| Douglas Barry | Chief Legal Officer | $2,094,450 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $3,391,059 |
| Adam Crystal | M.D., Ph.D. President of Research and Development | $3,110,646 |
| Alan Huang | Former Chief Scientific Officer | $1,770,905 |
| Daniella Beckman | Chief Financial Officer | $1,522,744 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $4,681,787 |
| Alan Huang | Former Chief Scientific Officer | $1,818,901 |
| Daniella Beckman | Chief Financial Officer | $1,516,879 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $11,515,974 |
| Daniella Beckman | Chief Financial Officer | $3,176,664 |
| Alan Huang | Chief Scientific Officer | $2,215,657 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Barbara Weber | President, Chief Executive Officer and Director | $958,221 |
| Daniella Beckman | Chief Financial Officer | $834,374 |
| Alan Huang | Chief Scientific Officer | $589,517 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Barbara Weber | member of Company's board of directors | Resigned | 2026-08-06 |
| Barbara Weber | Executive Chair | Terminated | 2026-08-06 |
| Robert Azelby | director of the Company | Appointed | 2026-06-23 |
| Sung Lee | Lead Independent Director | Appointed | 2026-05-13 |
| Kanishka Pothula | Board of Directors | Resigned | 2026-05-13 |
| Alexis Borisy | Board of Directors | Resigned | 2026-05-13 |
| Daniella Beckman | Chief Financial Officer, principal accounting officer and principal financial officer | Terminated | 2026-05-08 |
| Janice Kapty | SVP, Corporate Strategy and Project Leadership | Appointed | 2026-04-15 |
| Yen-Ching Chua | Chief Development Operations Officer | Appointed | 2026-04-15 |
| Jessica Newcomb | principal accounting officer | Appointed | 2026-04-15 |
| Matthew Gall | Chief Financial Officer | Appointed | 2026-04-15 |
| Barbara Weber, M.D. | Chief Executive Officer | Retired | 2026-01-08 |
| Malte Peters | President and Chief Executive Officer | Appointed | 2026-01-08 |
| Barbara Weber | Chief Executive Officer | Retired | 2026-01-08 |
| Malte Peters, M.D. | President and Chief Executive Officer | Appointed | 2026-01-08 |
| Barbara Weber, M.D. | Executive Chair | Appointed | 2026-01-08 |
| Sung H. Lee | director | Appointed | 2026-01-05 |
| Douglas Barry | Chief Legal and Compliance Officer and Corporate Secretary | Resigned | 2025-08-25 |
| John Ketchum | director of the Company | Appointed | 2023-08-30 |
| Aaron Davis | member of the Board of Directors | Resigned | 2023-08-30 |
| Jannik Andersen | Chief Scientific Officer | Appointed | 2023-08-07 |
| Adam Crystal, M.D., Ph.D. | President, Research & Development | Appointed | 2023-02-28 |